News & Events
-
December 18, 2018
Critical Path Institute Encouraged by FDA to Move Forward on Type 1 Diabetes Biomarker Initiative
Biomarker potentially could identify individuals at risk of developing T1D TUCSON, Ariz., December 18, 2018 — Critical Path Institute (C-Path) announced today that its Type 1 Diabetes (T1D) Consortium has received a positive response to its Letter of Intent (LOI) from the U.S. Food and Drug Administration (FDA) detailing the FDA’s decision to accept the... -
December 17, 2018
CPTR Newsletter – December 2018
CPTR Newsletter – December 2018 In this issue: In the Spotlight: TB-ReFLECT Manuscript Published Updates to the TB-PACTS Clinical Trial Data Repository Project Highlights: Application of the HFS-TB to Inform Regimen Development Programs Collaboration to Expand ReSeqTB Clinical Data Sets Supporting Global Surveillance of TB Resistance Progress with Regulatory Authorities LAM Biomarker Notes... - December 13, 2018
-
December 12, 2018
U.S. Food and Drug Administration Awards Contract to Critical Path Institute for Kidney Transplant Database
Patient-level data will inform the creation of drug development tools and speed development of new immunosuppressive treatments TUCSON, Ariz., December 12, 2018 — The U.S. Food and Drug Administration (FDA) has awarded a contract to Critical Path Institute (C-Path) in support of a new project to create a database of patient-level clinical trial data that... -
December 1, 2018
Brief Overview: Assessment of Compound-induced Acute Kidney Injury Using Animal Models, Biomarkers, and In Vitro Platforms
McDuffie, James E. “Brief Overview: Assessment of Compound-Induced Acute Kidney Injury Using Animal Models, Biomarkers, and In Vitro Platforms.” Toxicologic Pathology 46, no. 8 (December 2018): 978–90.
